These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The Skin-Brain Connection Hypothesis, Bringing Together CCL27-Mediated T-Cell Activation in the Skin and Neural Cell Damage in the Adult Brain. Blatt NL; Khaiboullin TI; Lombardi VC; Rizvanov AA; Khaiboullina SF Front Immunol; 2016; 7():683. PubMed ID: 28138328 [TBL] [Abstract][Full Text] [Related]
9. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430 [TBL] [Abstract][Full Text] [Related]
10. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Szczuciński A; Losy J Acta Neurol Scand; 2007 Mar; 115(3):137-46. PubMed ID: 17295707 [TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Link J Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782 [TBL] [Abstract][Full Text] [Related]
12. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. Saikali P; Antel JP; Pittet CL; Newcombe J; Arbour N J Immunol; 2010 Nov; 185(10):5693-703. PubMed ID: 20926794 [TBL] [Abstract][Full Text] [Related]
14. Emerging role of IL-16 in cytokine-mediated regulation of multiple sclerosis. Skundric DS; Cruikshank WW; Montgomery PC; Lisak RP; Tse HY Cytokine; 2015 Oct; 75(2):234-48. PubMed ID: 25703787 [TBL] [Abstract][Full Text] [Related]
15. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mellergård J; Edström M; Vrethem M; Ernerudh J; Dahle C Mult Scler; 2010 Feb; 16(2):208-17. PubMed ID: 20007431 [TBL] [Abstract][Full Text] [Related]
16. Neuronal injury in chronic CNS inflammation. Zindler E; Zipp F Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866 [TBL] [Abstract][Full Text] [Related]
17. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice. Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532 [TBL] [Abstract][Full Text] [Related]
18. Serum and Cerebrospinal Fluid Cytokine Biomarkers for Diagnosis of Multiple Sclerosis. Martynova E; Goyal M; Johri S; Kumar V; Khaibullin T; Rizvanov AA; Verma S; Khaiboullina SF; Baranwal M Mediators Inflamm; 2020; 2020():2727042. PubMed ID: 33162830 [TBL] [Abstract][Full Text] [Related]
19. Expression of TH1/TH2-related chemokine receptors on peripheral T cells and correlation with clinical disease activity in patients with multiple sclerosis. Nakajima H; Fukuda K; Doi Y; Sugino M; Kimura F; Hanafusa T; Ikemoto T; Shimizu A Eur Neurol; 2004; 52(3):162-8. PubMed ID: 15528917 [TBL] [Abstract][Full Text] [Related]
20. The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention. Burman J; Svensson E; Fransson M; Loskog AS; Zetterberg H; Raininko R; Svenningsson A; Fagius J; Mangsbo SM J Neuroimmunol; 2014 Dec; 277(1-2):153-9. PubMed ID: 25457841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]